GSK 329

Product Description

GSK 329 is a potent and selective TNNI3K (cardiac troponin I-interacting kinase) inhibitor (IC₅₀ = 10 nM). It exhibits selectivity for TNNI3K over human VEGFR2 (40-fold), p38α (80-fold), B-Raf (>200-fold) and displays >100-fold selectivity over 80% of 185 kinases tested. In vivo, GSK 329 reduces infarct size, ROS levels, and p38 activation in a mouse model of ischemia/reperfusion cardiac injury. This compound is orally bioavailable.

Solubility

Preparing Stock Solutions for GSK 329

The following data is based on the product molecular weight 472.25

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.12 mL	10.59 mL	21.18 mL
5 mM	0.42 mL	2.12 mL	4.24 mL
10 mM	0.21 mL	1.06 mL	2.12 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Vagnozzi Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci.Transl.Med. 2013 PMID: 24132636
• Patterson Identification of diarylurea inhibitors of the cardiac-specific kinase TNNI3K by designing selectivity against VEGFR2, p38a, and B-Raf. J.Med.Chem. 2021 PMID: 34699203